Agenus Inc (AGEN)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Garo H. Armen
Employees:
294
3 FORBES ROAD, LEXINGTON, MA 02421
781-674-4410

Agenus, Inc. is a biotechnology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its core technology portfolio consists of Saponin platform and Heat Shock Protein platform. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 1994 and is headquartered in Lexington, MA.

Data derived from most recent annual or quarterly report
Market Cap 783.335 Million Shares Outstanding256.831 Million Avg 30-day Volume 4.477 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-0.37
Price to Revenue7.1382 Debt to Equity-0.1162 EBITDA-123.934 Million
Price to Book Value0.0 Operating Margin-154.7197 Enterprise Value520.357 Million
Current Ratio0.98 EPS Growth0.179 Quick Ratio0.878
1 Yr BETA 1.3333 52-week High/Low 6.79 / 2.5 Profit Margin-226.5464
Operating Cash Flow Growth-13.532 Altman Z-Score-9.6665 Free Cash Flow to Firm -72.093 Million
View SEC Filings from AGEN instead.

View recent insider trading info

Funds Holding AGEN (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding AGEN BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

38.7 Thousand total shares from 1 transactions

Exercise Derivative Conversion (M)

100 Thousand total shares from 1 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

O'DAY STEVEN J CHIEF MEDICAL OFFICER

  • Officer
61,321 2022-01-04 3

WIINBERG ULF

  • Director
120,690 2022-01-03 5

JORDAN WADIH

  • Director
206,114 2022-01-03 4

WRIGHT TIMOTHY

  • Director
134,895 2022-01-03 5

HIRSCH SUSAN B

  • Director
21,571 2022-01-03 4

ARMEN GARO H CHAIRMAN AND CEO

  • Officer
  • Director
1,900,000 2022-01-02 15

KLASKIN CHRISTINE M PFO & PAO

  • Officer
100,000 2022-01-02 4

CORVESE BRIAN

  • Director
108,085 2021-06-16 2

JEYNES-ELLIS ALLISON M

  • Director
66,176 2021-06-16 2

BUELL JENNIFER COO AND PRESIDENT

  • Officer
1,027,091 2021-06-15 2

KRAUSS ADAM CHIEF LEGAL OFFICER

  • Officer
175,000 2021-06-15 1

CLARK PAUL N

  • Director
5,093 2021-04-01 1

KEARNS EVAN VP AND GENERAL COUNSEL

  • Officer
0 2020-12-17 0

INCYTE CORP

  • 10% Owner
No longer subject to file 2020-06-16 0

DUNCAN ALEX CHIEF TECHNOLOGY OFFICER

  • Officer
0 2019-07-23 0

CORTIS CHRISTIAN CHIEF STRATEGY OFFICER

  • Officer
0 2019-07-23 0

VALENTINE KAREN CHIEF LEGAL OFFICER AND GC

  • Officer
0 2018-06-20 0

BAYSAL OZER CHIEF COMMERCIAL OFFICER

  • Officer
0 2018-06-20 0

SHARP SHALINI

  • Director
0 2018-03-02 0

STEIN ROBERT BENJAMIN PRESIDENT R&D

  • Officer
No longer subject to file 2017-03-31 0

CUILLEROT JEAN-MARIE CHIEF MEDICAL OFFICER

  • Officer
0 2017-03-31 0

MALIK SHAHZAD

  • Director
0 2016-06-15 0

BALLANTYNE CHARLES EVAN CFO

  • Officer
0 2016-06-14 0

DECHAENE TOM

  • Director
No longer subject to file 2016-01-04 0

QVT ASSOCIATES GP LLC

QVT FUND V LP

  • 10% Owner
No longer subject to file 2015-01-09 0

WENTWORTH KERRY VP, CLINICAL, REG & QUAL

  • Officer
57,410 2014-02-26 0

ROTHWELL TIMOTHY G

  • Director
No longer subject to file 2011-12-08 0

HATSOPOULOS JOHN

  • Director
No longer subject to file 2011-12-08 0

LEVITSKY HYAM

  • Director
No longer subject to file 2011-08-28 0

MARGARET EISEN

  • Director
No longer subject to file 2009-06-11 0

THORNTON PETER

  • Director
0 2008-06-05 0

INVUS PUBLIC EQUITIES, LP

INVUS PUBLIC EQUITIES ADVISORS, LLC

ULYS, LLC

DEBBANE RAYMOND

  • 10% Owner
3,533,333 2008-05-10 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

O'DAY STEVEN J - Officer CHIEF MEDICAL OFFICER

2022-01-06 17:47:32 -0500 2022-01-06 S 38,679 $3.06 d 61,321 direct 1.3378 2.0067 3.3445 3 -3.3445 5

O'DAY STEVEN J - Officer CHIEF MEDICAL OFFICER

2022-01-06 17:47:32 -0500 2022-01-04 M 100,000 d 0 direct

O'DAY STEVEN J - Officer CHIEF MEDICAL OFFICER

2022-01-06 17:47:32 -0500 2022-01-04 M 100,000 a 100,000 direct 1.3378 2.0067 3.3445 3 -3.3445 5

HIRSCH SUSAN B - Director

2022-01-05 14:59:03 -0500 2022-01-03 A 4,677 $4.01 a 21,571 direct 2.3333 -0.3333 3.0 5 -0.3333 3

JORDAN WADIH - Director

2022-01-05 15:25:33 -0500 2022-01-03 A 6,548 a 206,114 direct

WIINBERG ULF - Director

2022-01-05 15:24:08 -0500 2022-01-03 A 6,392 a 120,690 direct

WRIGHT TIMOTHY - Director

2022-01-05 15:10:14 -0500 2022-01-03 A 2,339 a 134,895 direct

ARMEN GARO H - Director - Officer CHAIRMAN AND CEO

2022-01-04 18:45:13 -0500 2022-01-02 A 1,900,000 a 1,900,000 direct

KLASKIN CHRISTINE M - Officer PFO & PAO

2022-01-04 21:02:49 -0500 2022-01-02 A 100,000 a 100,000 direct

O'DAY STEVEN J - Officer CHIEF MEDICAL OFFICER

2022-01-04 18:43:19 -0500 2022-01-02 A 150,000 a 150,000 direct

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
AGENUS INC AGEN 2022-01-17 21:45:03 UTC -0.2744 0.3444 4900000
AGENUS INC AGEN 2022-01-17 21:15:03 UTC -0.2744 0.3444 4900000
AGENUS INC AGEN 2022-01-17 20:45:03 UTC -0.2744 0.3444 4900000
AGENUS INC AGEN 2022-01-17 20:15:04 UTC -0.2744 0.3444 4900000
AGENUS INC AGEN 2022-01-17 19:45:03 UTC -0.2744 0.3444 4900000
AGENUS INC AGEN 2022-01-17 19:15:03 UTC -0.2744 0.3444 4900000
AGENUS INC AGEN 2022-01-17 18:45:03 UTC -0.2744 0.3444 4900000
AGENUS INC AGEN 2022-01-17 18:15:03 UTC -0.2744 0.3444 4900000
AGENUS INC AGEN 2022-01-17 17:45:03 UTC -0.2744 0.3444 4900000
AGENUS INC AGEN 2022-01-17 17:15:03 UTC -0.2744 0.3444 4900000
AGENUS INC AGEN 2022-01-17 16:45:03 UTC -0.2744 0.3444 4900000
AGENUS INC AGEN 2022-01-17 16:15:04 UTC -0.2744 0.3444 4900000
AGENUS INC AGEN 2022-01-17 15:45:03 UTC -0.2744 0.3444 4900000
AGENUS INC AGEN 2022-01-17 15:15:03 UTC -0.2744 0.3444 4900000
AGENUS INC AGEN 2022-01-17 14:45:03 UTC -0.2744 0.3444 4900000
AGENUS INC AGEN 2022-01-17 14:15:03 UTC -0.2744 0.3444 4900000
AGENUS INC AGEN 2022-01-17 13:45:03 UTC -0.2744 0.3444 4900000
AGENUS INC AGEN 2022-01-17 13:15:03 UTC -0.2744 0.3444 4900000
AGENUS INC AGEN 2022-01-17 12:45:03 UTC -0.2744 0.3444 4900000
AGENUS INC AGEN 2022-01-14 22:15:03 UTC -0.2744 0.3444 4900000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments